Splenic switch-off as a novel marker for adenosine response in nitrogen-13 ammonia PET myocardial perfusion imaging: Cross-validation against CMR using a hybrid PET/MR device.


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
06 2022
Historique:
received: 28 05 2020
accepted: 09 11 2020
pubmed: 24 12 2020
medline: 7 6 2022
entrez: 23 12 2020
Statut: ppublish

Résumé

No methodology is available to distinguish truly reduced myocardial flow reserve (MFR) in positron emission tomography myocardial perfusion imaging (PET MPI) from seemingly impaired MFR due to inadequate adenosine response. The adenosine-induced splenic switch-off (SSO) sign has been proposed as a potential marker for adequate adenosine response in cardiac magnetic resonance (CMR). We assessed the feasibility of detecting SSO in nitrogen-13 ammonia PET MPI using SSO in CMR as the standard of reference. Fifty patients underwent simultaneous CMR and PET MPI on a hybrid PET/MR device with co-injection of a gadolinium-based contrast agent and nitrogen-13 ammonia during rest and adenosine-induced stress. In CMR, SSO was assessed visually (positive vs negative SSO) and quantitatively by calculating the ratio of the peak signal intensity of the spleen during stress over rest (SIR). In PET MPI, the splenic signal activity ratio (SAR) was calculated as the maximal standard uptake value of the spleen during stress over rest. The median SIR was significantly lower in patients with positive versus negative SSO in CMR (0.57 [IQR 0.49 to 0.62] vs 0.89 [IQR 0.76 to 0.98]; P < .001). Similarly, median SAR in PET MPI was significantly lower in patients with positive versus negative SSO (0.40 [IQR 0.32 to 0.45] vs 0.80 [IQR 0.47 to 0.98]; P < .001). Similarly to CMR, SSO can be detected in nitrogen-13 ammonia PET MPI. This might help distinguish adenosine non-responders from patients with truly impaired MFR due to microvascular dysfunction or multivessel coronary artery disease.

Sections du résumé

BACKGROUND
No methodology is available to distinguish truly reduced myocardial flow reserve (MFR) in positron emission tomography myocardial perfusion imaging (PET MPI) from seemingly impaired MFR due to inadequate adenosine response. The adenosine-induced splenic switch-off (SSO) sign has been proposed as a potential marker for adequate adenosine response in cardiac magnetic resonance (CMR). We assessed the feasibility of detecting SSO in nitrogen-13 ammonia PET MPI using SSO in CMR as the standard of reference.
METHODS AND RESULTS
Fifty patients underwent simultaneous CMR and PET MPI on a hybrid PET/MR device with co-injection of a gadolinium-based contrast agent and nitrogen-13 ammonia during rest and adenosine-induced stress. In CMR, SSO was assessed visually (positive vs negative SSO) and quantitatively by calculating the ratio of the peak signal intensity of the spleen during stress over rest (SIR). In PET MPI, the splenic signal activity ratio (SAR) was calculated as the maximal standard uptake value of the spleen during stress over rest. The median SIR was significantly lower in patients with positive versus negative SSO in CMR (0.57 [IQR 0.49 to 0.62] vs 0.89 [IQR 0.76 to 0.98]; P < .001). Similarly, median SAR in PET MPI was significantly lower in patients with positive versus negative SSO (0.40 [IQR 0.32 to 0.45] vs 0.80 [IQR 0.47 to 0.98]; P < .001).
CONCLUSION
Similarly to CMR, SSO can be detected in nitrogen-13 ammonia PET MPI. This might help distinguish adenosine non-responders from patients with truly impaired MFR due to microvascular dysfunction or multivessel coronary artery disease.

Identifiants

pubmed: 33354759
doi: 10.1007/s12350-020-02448-y
pii: 10.1007/s12350-020-02448-y
pmc: PMC9163112
doi:

Substances chimiques

Nitrogen Radioisotopes 0
Nitrogen-13 0
Ammonia 7664-41-7
Adenosine K72T3FS567

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1205-1214

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020. The Author(s).

Références

JACC Cardiovasc Imaging. 2017 May;10(5):578-581
pubmed: 28017391
Int J Cardiovasc Imaging. 2018 Apr;34(4):625-632
pubmed: 29177579
J Cardiovasc Magn Reson. 2017 Jan 13;19(1):1
pubmed: 28081721
J Am Coll Cardiol. 2005 Feb 15;45(4):553-8
pubmed: 15708703
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
J Nucl Cardiol. 2017 Dec;24(6):2064-2128
pubmed: 28916938
J Nucl Med. 1990 Dec;31(12):1899-905
pubmed: 2266384
J Cardiovasc Magn Reson. 2019 Jun 24;21(1):33
pubmed: 31230593
Radiology. 2015 Sep;276(3):732-40
pubmed: 25923223
Circulation. 2003 Apr 15;107(14):1877-83
pubmed: 12668522
J Magn Reson Imaging. 2016 Mar;43(3):566-73
pubmed: 26285057
J Nucl Cardiol. 2019 Dec;26(6):1898-1900
pubmed: 29948893
J Nucl Cardiol. 2019 Dec;26(6):1888-1897
pubmed: 29651739
J Am Coll Cardiol. 2012 Oct 30;60(18):1828-37
pubmed: 23040573
Am J Cardiol. 1997 May 15;79(10):1319-22
pubmed: 9165150
Eur Heart J Cardiovasc Imaging. 2017 Nov 01;18(11):1216-1221
pubmed: 28329392
J Nucl Cardiol. 2019 Aug;26(4):1107-1118
pubmed: 29168158
J Am Coll Cardiol. 1984 May;3(5):1205-11
pubmed: 6707370
Purinergic Signal. 2008 Sep;4(3):267-85
pubmed: 18443747
J Nucl Med. 2012 Aug;53(8):1230-4
pubmed: 22776752

Auteurs

Adam Bakula (A)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Dimitri Patriki (D)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Elia von Felten (E)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Georgios Benetos (G)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Aleksandra Sustar (A)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Dominik C Benz (DC)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Muriel Wiedemann-Buser (M)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Valerie Treyer (V)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Aju P Pazhenkottil (AP)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Christoph Gräni (C)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Catherine Gebhard (C)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Philipp A Kaufmann (PA)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Ronny R Buechel (RR)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Tobias A Fuchs (TA)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland. tobiasfuchs@gmx.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH